Pathophysiology of severe primary graft dysfunction in orthotopic heart transplantation

2021 ◽  
Author(s):  
Hoong Sern Lim ◽  
Aaron Ranasinghe ◽  
David Quinn ◽  
Colin D Chue ◽  
Jorge Mascaro
Keyword(s):  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction

A Novel Risk Scoring System for Predicting Primary Graft Dysfunction after Orthotopic Heart Transplantation

2020 ◽  
Vol 26 (10) ◽  
pp. S136-S137
Author(s):  
Syed Adeel Ahsan ◽  
Jasjit Bhinder ◽  
Syed Zaid ◽  
Parija Sharedalal ◽  
Chhaya Aggarwal-Gupta ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Scoring System ◽  
Orthotopic Heart Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Risk Scoring ◽  
Risk Scoring System

Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation

2017 ◽  
Vol 36 (11) ◽  
pp. 1226-1233 ◽  
Author(s):  
Matthew Wright ◽  
Koji Takeda ◽  
Christine Mauro ◽  
Douglas Jennings ◽  
Paul Kurlansky ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Dose Dependent

scholarly journals Experience of ECMO in Primary Graft Dysfunction after Orthotopic Heart Transplantation

2015 ◽  
Author(s):  
Elson Borges Lima ◽  
Claudio Ribeiro da Cunha ◽  
Vitor Salvatore Barzilai ◽  
Marcelo Botelho Ulhoa ◽  
Maria Regina de Barros ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Orthotopic Heart Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction

Does the New ISHLT Primary Graft Dysfunction (PGD) Grading Scale in Heart Transplantation Predict Outcome?

2017 ◽  
Vol 36 (4) ◽  
pp. S146
Author(s):  
J. Patel ◽  
M. Kittleson ◽  
T. Aintablian ◽  
R. Levine ◽  
M. Curry ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Grading Scale

Plasma Levels of SERCA2a as a Noninvasive Biomarker of Primary Graft Dysfunction After Heart Transplantation

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Silvia Lozano-Edo ◽  
Ignacio Sánchez-Lázaro ◽  
Manuel Portolés ◽  
Esther Roselló-Lletí ◽  
Estefania Tarazón ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Plasma Levels ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Noninvasive Biomarker

scholarly journals Primary Graft Dysfunction after Heart Transplantation with High Frequency of Marginal Donor Hearts

2016 ◽  
Vol 35 (4) ◽  
pp. S298 ◽  
Author(s):  
H. Hata ◽  
T. Fujita ◽  
H. Ishibashi-Ueda ◽  
N. Fukushima ◽  
T. Nakatani ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
High Frequency ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Marginal Donor

Abstract 13933: High Urgency Candidates for Heart Transplantation Does Not Correlate to the Development of Primary Graft Dysfunction

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Rafael Skorka ◽  
Keith Nishihara ◽  
Adriana Shen ◽  
Evan P Kransdorf ◽  
Lillian Benck ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Heart Transplant ◽  
Survival Rates ◽  
Control Group ◽  
High Dose ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Assist Device ◽  
Transplant Patients ◽  
High Urgency

Introduction: Primary Graft Dysfunction (PGD) after Heart Transplantation (HTx) is seen in approximately 7-30% of heart transplant patients as described by the literature. Many of these patients have severe PGD which requires support with ECMO. It has been reported that patients who are severely ill on high dose inotropes or on assists devices have greater propensity to develop severe PGD. Many of these patients have borderline blood pressure due to poor cardiac function which may contribute to PGD with its associated vasoplegia. In order to asses risk for the development of PGD we evaluated our patients in terms of their status at the time of transplant to assess risk. Methods: Between 2010 and 2019 we assessed 44 Heart Transplant patients who developed severe PGD immediately after HTx. The UNOS Status at the time of Transplant was recorded along with the presence of a durable assist device, temporary assist device, or no Inotropes or assist device. 30 Day and 1 Year survival were assessed for all status groups including a control group (no PGD, n=799). Results: High urgency status at the time of transplant was not the overwhelming majority of patients that developed severe PGD. Approximately 32% of these patients were patients who were waiting for transplant at home, who were not on Intravenous Inotropes and not on assist devices. 1 Year survival was compromised in all patients who developed severe PGD with survival rates that were significantly lower than patients without PGD in our program (47.7% vs 93.6%, p<0.001) (see Table). Conclusions: High urgency status is not solely associated with the development of severe PGD. Further assessment into these non-urgent patients who develop severe PGD is warranted and is under investigation. Inflammatory markers should be assessed in all patients who develop severe PGD.

Sign in / Sign up

Export Citation Format

Share Document